explore -WSS

explore

author：focus 2025-09-30 16:28:08 - browse：23185

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： What the cancer research community can learn from the Covid response

knowledge

WSS

Readout LOUD podcast: What to know about H5N1 bird flu

Use wet bulb globe temperature, not heat index, to protect workers

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Nearly two

Humana, CVS hope to turn members into patients at clinics

After gene therapy, two congenitally deaf children hear for the first time

focus

explore

entertainment

Medicare details structure of new drug price negotiation program

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Medical leaders decry Supreme Court decision on affirmative action

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

How one medical school became remarkably diverse

TytoCare raises $49 million to build out AI

Heart attack and stroke risk calculators need revising

What the cancer research community can learn from the Covid response

Duchenne breakthrough therapy leaves behind pioneering families

OTC birth control: A brief history of over the counter pill design

Wikipedia

ProMED, early warning system on disease outbreaks, in peril

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Elevance, private equity launch primary care company

ProMED, early warning system on disease outbreaks, in peril

Dramatically reducing cancer deaths requires the PASTEUR Act

hotspot

knowledge

Wikipedia

leisure time